2. Search Result
Search Result
Results for "

PKC+inhibitor

" in MedChemExpress (MCE) Product Catalog:

71

Inhibitors & Agonists

3

Peptides

16

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13689
    Go 6983
    Maximum Cited Publications
    82 Publications Verification

    Gö 6983; Goe 6983

    		 PKC Cancer
    Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.
    Go 6983
  • HY-13867
    Bisindolylmaleimide I
    35+ Cited Publications

    GF109203X; Go 6850

    		 PKC GSK-3 Metabolic Disease Cancer
    Bisindolylmaleimide I (GF109203X) is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I is also a GSK-3 inhibitor .
    Bisindolylmaleimide I
  • HY-10343
    Sotrastaurin
    20+ Cited Publications

    AEB071

    		 MARCKS PKC Inflammation/Immunology Cancer
    Sotrastaurin (AEB071) is a potent and orally-active pan-PKC inhibitor, with Kis of 0.22 nM, 0.64 nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively .
    Sotrastaurin
  • HY-101569
    Darovasertib
    4 Publications Verification

    LXS196; IDE196

    		 PKC Cancer
    Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research .
    Darovasertib
  • HY-18980
    Rottlerin
    Maximum Cited Publications
    22 Publications Verification

    Mallotoxin; NSC 56346; NSC 94525

    		 PKC Autophagy Apoptosis HIV RABV Infection Cancer
    Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC50 values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation . Rottlerin inhibits HIV-1 integration and Rabies virus (RABV) infection .
    Rottlerin
  • HY-10183
    Go6976
    10+ Cited Publications

    		 PKC Influenza Virus Cancer
    Go6976 is a Protein Kinase C (PKC) inhibitor, with an IC50 of 20 nM.
    Go6976
  • HY-N0152
    Myricitrin
    3 Publications Verification

    		 PKC NO Synthase TNF Receptor Parasite Infection Neurological Disease Inflammation/Immunology
    Myricitrin, a naturally occurring flavonoid, is an orally active nitric oxide (NO) and PKC inhibitor. Myricitrin has central nervous system activity, including anxiolytic-like action. Myricitrin possesses antioxidant, anti-inflammatory, antifibrotic and anti-malarial effects .
    Myricitrin
  • HY-162472
    XRD-0394

    		ATM/ATR DNA-PK Cancer
    XRD-0394 is a potent and orally active dual ATM and DNA-PKcs inhibitor with IC50s of 0.39 nM and 0.89 nM, respectively. XRD-0394 shows selectivity over other PIKK and PI3K family members. XRD-0394 significantly enhances tumor cell killing in vitro and in vivo under therapeutic ionizing radiation conditions. XRD-0394 can potentiate the effects of PARP and topoisomerase I inhibitors in vitro .
    XRD-0394
  • HY-13866
    Ro 31-8220 mesylate
    10+ Cited Publications

    Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate

    		 PKC JNK Cardiovascular Disease Neurological Disease Cancer
    Ro 31-8220 mesylate is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220 mesylate can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC .
    Ro 31-8220 mesylate
  • HY-113202
    Stearoylcarnitine
    1 Publications Verification

    		 Endogenous Metabolite PKC GlyT Neurological Disease Metabolic Disease
    Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .
    Stearoylcarnitine
  • HY-100618
    Hispidin
    1 Publications Verification

    		 PKC Endogenous Metabolite Ferroptosis Reactive Oxygen Species (ROS) p38 MAPK JAK STAT JNK Akt GSK-3 ERK Keap1-Nrf2 Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Hispidin, a PKC inhibitor and a phenolic compound can be found in Phellinus linteus, has been shown to possess strong anti-oxidant, anti-cancer, anti-diabetic, and anti-dementia properties .
    Hispidin
  • HY-117610A
    Bisindolylmaleimide XI hydrochloride
    3 Publications Verification

    Ro 32-0432; Ro 31-8830 hydrochloride

    		 PKC Inflammation/Immunology
    Bisindolylmaleimide XI hydrochloride (Ro 32-0432) is a potent, selective and orally active PKC inhibitor with IC50s of 9 nM, 28 nM, 31 nM, 37 nM, and 108 nM for PKCα, PKCβI, PKCβII, PKCγ, and PKCε, respectively .
    Bisindolylmaleimide XI hydrochloride
  • HY-12798C
    AR-13503

    AR-13324 M1 metabolite

    		 PKC ROCK Cardiovascular Disease Neurological Disease
    AR-13503 (AR-13324 M1 metabolite) is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research .
    AR-13503
  • HY-108254
    Bisindolylmaleimide IV

    Arcyriarubin A

    		 PKC CMV Infection
    Bisindolylmaleimide IV (Arcyriarubin A) is a potent protein kinase C (PKC) inhibitor, with IC50s ranging from 0.1 to 0.55 μM. Bisindolylmaleimide IV also inhibits PKA (IC50=3.1-11.8μM) . Bisindolylmaleimide IV is a potent, selective inhibitor of human cytomegalovirus (HCMV) replication in cell culture with an IC50 of 0.2 μM .
    Bisindolylmaleimide IV
  • HY-N2575
    Hypocrellin A
    2 Publications Verification

    		 PKC Bacterial Parasite HIV VSV VEGFR Bcl-2 Family Apoptosis Infection Metabolic Disease Cancer
    Hypocrellin A is a PKC inhibitor that exerts antidiabetic activity by reversing the effects of high glucose on endothelin (ET-1) expression. Hypocrellin A is also a photosensitizer for photodynamic therapy (PDT) with anticancer, antibacterial and antiviral activities, especially against human immunodeficiency virus (HIV). In addition, Hypocrellin-A also possesses anti-Leishmania activity (IC50=0.27 μg/ml) .
    Hypocrellin A
  • HY-13661
    7-Hydroxystaurosporine
    1 Publications Verification

    UCN-01; KRX-0601

    		 PKC CDK Apoptosis Cadherin Neurological Disease Cancer
    7-Hydroxystaurosporine (UCN-01), a derivative of Staurosporine (HY-15141), is a selective protein kinase C (PKC) inhibitor with antitumor activity. 7-hydroxystaurosporine induces apoptosis and inhibits cell proliferation in colon carcinoma and leukemia cells, suppresses invasion and migration in glioblastoma cells. 7-Hydroxystaurosporine exhibits efficacy in breast cancer xenograft mouse models. 7-Hydroxystaurosporine can be used for colon carcinoma, breast cancer, glioblastoma and leukemia research .
    7-Hydroxystaurosporine
  • HY-11009
    CGP60474
    5+ Cited Publications

    		 CDK PKC Cancer
    CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .
    CGP60474
  • HY-108136A
    Bisindolylmaleimide X hydrochloride
    2 Publications Verification

    BIM-X hydrochloride; Ro31-8425 hydrochloride

    		 PKC CDK Cardiovascular Disease Inflammation/Immunology Cancer
    Bisindolylmaleimide X hydrochloride(Ro 31-8425 hydrochloride, BIM-X hydrochloride) is a cell-penetrating PKC inhibitor. Bisindolylmaleimide X hydrochloride is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM. Bisindolylmaleimide X hydrochloride inhibits the proliferation of CD4 T cells in vitro. Bisindolylmaleimide X hydrochloride inhibits eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. Bisindolylmaleimide X hydrochloride can be used for research on the immune system and cardiovascular diseases .
    Bisindolylmaleimide X hydrochloride
  • HY-13867A
    Bisindolylmaleimide I hydrochloride
    35+ Cited Publications

    GF109203X hydrochloride; Go 6850 hydrochloride

    		 PKC GSK-3 Metabolic Disease Cancer
    Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I hydrochloride is also a GSK-3 inhibitor .
    Bisindolylmaleimide I hydrochloride
  • HY-129099A
    N-Desmethyltamoxifen hydrochloride

    		PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite Cancer
    N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .
    N-Desmethyltamoxifen hydrochloride
  • HY-105416
    Calphostin C
    2 Publications Verification

    UCN-1028C

    		 Antibiotic PKC Apoptosis Metabolic Disease Cancer
    Calphostin C is a highly selective PKC inhibitor (IC50=0.05 μM) and tumor apoptosis inducer. Calphostin C competitively binds to PKC and inhibits PKC-mediated phosphorylation signal transduction. Calphostin C restores Na+/K+ ATPase activity in the sciatic nerve of diabetic mice and improves neuropathy. Calphostin C can be used in the study of anti-tumor and diabetic complications .
    Calphostin C
  • HY-129624A
    Bisindolylmaleimide VIII acetate
    1 Publications Verification

    Ro 31-7549 acetate; Bis VIII acetate

    		 PKC Apoptosis Inflammation/Immunology Cancer
    Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective protein kinase C (PKC) inhibitor with an IC50 of 158 nM for rat brain PKC. Bisindolylmaleimide VIII acetate has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively . Bisindolylmaleimide VIII acetate facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases .
    Bisindolylmaleimide VIII acetate
  • HY-18713A
    CRT0066854 hydrochloride

    		PKC ROCK Neurological Disease
    CRT0066854 hydrochloride is a potent and selective atypical PKCs inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively .
    CRT0066854 hydrochloride
  • HY-117366
    PS432

    		PKC Cancer
    PS432 is a PKC inhibitor with IC50s of 16.9 μM (PKCι) and 18.5 μM (PKCζ), respectively. PS432 effectively inhibits the proliferation of non-small cell lung cancer cells (NSCLCs) and tumor growth in mouse xenograft models .
    PS432
  • HY-108262
    UCN-02

    7-epi-Hydroxystaurosporine

    		 PKC PKA Cancer
    UCN-02 (7-epi-Hydroxystaurosporine) is a selective protein kinase C (PKC) inhibitor with a PKC IC50 value of 62 nM and a PKA IC50 value of 0.25 μM. UCN-02 can be produced by Streptomyces strain N-126. UCN-02 can be used for the research of breast carcinoma .
    UCN-02
  • HY-101195
    DL-erythro-Dihydrosphingosine

    		PKC Phospholipase Bcl-2 Family Apoptosis MMP Inflammation/Immunology Cancer
    DL-erythro-Dihydrosphingosine is a sphingosine-based PKC inhibitor. DL-erythro-Dihydrosphingosine directly inhibits the enzymatic activity of PLA2. DL-erythro-Dihydrosphingosine inhibits the activity of Bcl-2 protein involved in apoptosis. DL-erythro-Dihydrosphingosine inhibits the activity of matrix metalloproteinases (MMP). DL-erythro-Dihydrosphingosine is applicable for research on cancer and inflammatory diseases .
    DL-erythro-Dihydrosphingosine
  • HY-13866B
    Ro 31-8220 formic
    10+ Cited Publications

    Bisindolylmaleimide IX formic

    		 PKC JNK Cancer
    Ro 31-8220 formic is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 formic also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively). Ro 31-8220 formic can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC .
    Ro 31-8220 formic
  • HY-125639
    (rac)-AR-13503

    (rac)-AR-13324 M1 metabolite

    		 PKC ROCK Cardiovascular Disease
    (rac)-AR-13503 ((rac)-AR-13324 M1 metabolite) is the isoform of AR-13503 (HY-12798C). AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice .
    (rac)-AR-13503
  • HY-13866A
    Ro 31-8220

    Bisindolylmaleimide IX

    		 PKC JNK Cardiovascular Disease Neurological Disease
    Ro 31-8220 is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220 can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC .
    Ro 31-8220
  • HY-129980
    NPC-15437 dihydrochloride

    		PKC Neurological Disease
    NPC-15437 dihydrochloride is a selective, penetrable and reversible protein kinase C (PKC) inhibitor, with an IC50 of 19 μM. NPC-15437 dihydrochloride interferes with mechanisms underlying memory consolidation .
    NPC-15437 dihydrochloride
  • HY-129099
    N-Desmethyltamoxifen

    		PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite Cancer
    N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .
    N-Desmethyltamoxifen
  • HY-N6736
    K-252c

    		Beta-lactamase PKC Bacterial Apoptosis Infection Cancer
    K-252c, a staurosporine analog isolated from Nocardiopsis sp., is a cell-permeable PKC inhibitor, with an IC50 of 2.45 µM. K-252c induces apoptosis in human chronic myelogenous leukemia cancer cells. K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase .
    K-252c
  • HY-108601A
    (S)-Ro 32-0432

    		PKC Neurological Disease Inflammation/Immunology
    (S)-Ro 32-0432 is a potent, selective, ATP-competitive and orally active PKC inhibitor. The IC50 values of (S)-Ro 32-0432 for PKCα, PKCβI, PKCβII, PKCγ and PKCε are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. (S)-Ro 32-0432 is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. (S)-Ro 32-0432 prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research .
    (S)-Ro 32-0432
  • HY-P3770
    Phosphate acceptor peptide

    		PKC Others
    Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .
    Phosphate acceptor peptide
  • HY-120515
    7-Oxostaurosporine

    		PKC Cancer
    7-Oxostaurosporine is a potent protein kinase C (PKC) inhibitor that effectively inhibits tumor growth by inducing apoptosis and inhibiting the nuclear factor (NF)-κB/p-p65 pathway .
    7-Oxostaurosporine
  • HY-118442
    Sphingosine (d14:1)

    Tetradecasphing-4-enine

    		 PKC Cancer
    Sphingosine (d14:1) (Tetradecasphing-4-enine), a sphingolipid, is a potent Protein kinase C (PKC) inhibitor. Sphingosine (d14:1) prevents its interaction with sn-1,2-diacylglycerol (DAG)/Phorbol esters .
    Sphingosine (d14:1)
  • HY-13867R
    Bisindolylmaleimide I (Standard)

    GF109203X (Standard); Go 6850 (Standard)

    		 PKC GSK-3 Reference Standards Metabolic Disease Cancer
    Bisindolylmaleimide I (Standard) is the analytical standard of Bisindolylmaleimide I. This product is intended for research and analytical applications. Bisindolylmaleimide I (GF109203X) is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I is also a GSK-3 inhibitor .
    Bisindolylmaleimide I (Standard)
  • HY-13689R
    Go 6983 (Standard)

    Gö 6983 (Standard); Goe 6983 (Standard)

    		 PKC Reference Standards Cancer
    Go 6983 (Standard) is the analytical standard of Go 6983. This product is intended for research and analytical applications. Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.
    Go 6983 (Standard)
  • HY-P3083
    N-Myristoyl-Lys-Arg-Thr-Leu-Arg

    		PKC Inflammation/Immunology
    N-Myristoyl-Lys-Arg-Thr-Leu-Arg is a protein kinase C (PKC) inhibitor with an IC50 value of 75 μM. N-Myristoyl-Lys-Arg-Thr-Leu-Arg inhibits IL-2 receptor induction and IL-2 production in the human leukemic cell line Jurkat .
    N-Myristoyl-Lys-Arg-Thr-Leu-Arg
  • HY-139466
    PF-03622905

    		SHP2 PKC Metabolic Disease
    PF-03622905 is a potent and ATP-competitive PKC inhibitor with IC50s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM, and 74.1 nM for PKCα, PKCβI, PKCβII, PKCγ, and PKCθ, respectively. PF-03622905 shows high specificity for PKC over other protein kinases .
    PF-03622905
  • HY-124308
    PS315

    		PKC Cancer
    PS315, a derivative of PS48 (HY-15967), is an allosteric PKC inhibitor by binding to the PIF-pocket of aPKC and inducing a displacement of the active site residue Lys111. PS315 inhibits the full-length and catalytic domain constructs of PKCζ (IC50=10 μM) and PKCη (IC50=30 μM). PS315 has anti-cancer activity .
    PS315
  • HY-139467
    PF-04577806

    		SHP2 PKC Metabolic Disease
    PF-04577806 is a potent, selective and ATP competitive PKC inhibitor. PF-04577806 shows potent inhibitory activity towards PKCα, PKCβI, PKCβII, PKCγ, and PKCθ with IC50s of 2.4 nM, 8.1 nM, 6.9 nM, 45.9 nM, and 29.5 nM, respectively. PF-04577806 can reverse retinal vascular leakage in diabetic rats .
    PF-04577806
  • HY-113202S
    Stearoyl-L-carnitine-d3

    		Isotope-Labeled Compounds Endogenous Metabolite PKC GlyT Neurological Disease Metabolic Disease
    Stearoyl-L-carnitine-d3 is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .
    Stearoyl-L-carnitine-d3
  • HY-169578
    PKC-IN-5

    		PKC Cancer
    PKC-IN-5 (Compound PKCe2054) is a PKC inhibitor. PKC-IN-5 prevents the interaction between PKCe and its adaptor protein RACK2 .
    PKC-IN-5
  • HY-P5886
    PKC 20-28,myristoylated

    Myristoylated protein kinase C inhibitor 20-28

    		 PKC Cancer
    PKC 20-28,myristoylated (Myristoylated protein kinase C inhibitor 20-28) is a cell-permeable PKC inhibitor that can be used in cancer research .
    PKC 20-28,myristoylated
  • HY-116060
    RK-286D

    		Antibiotic PKC Bacterial Fungal Infection
    RK-286D is an antibiotic and a PKC inhibitor with antimicrobial activity. RK-286D shows inhibitory activities against bleb formation induced by PDBu (HY-18985) and in vitro PKC activity .
    RK-286D
  • HY-N8475
    6-Deoxyisojacareubin

    		PKC Cancer
    6-Deoxyisojacareubin is a PKC inhibitor that inhibits the proliferation of QGY-7703 cells in a concentration-dependent manner. 6-Deoxyisojacareubin is also a natural product that can be obtained from Garcinia nervosa. 6-Deoxyisojacareubin can be used in cancer research .
    6-Deoxyisojacareubin
  • HY-122241
    MT477

    		PKC Cancer
    MT477 is a potent protein kinase C (PKC) inhibitor. MT477 induces apoptosis and necrosis. MT477 decreases the protein expression of Ras-GTP, p-Erk1/2, p-Elk1. MT477 shows antitumor activity .
    MT477
  • HY-N6734
    K-252b

    		PKC Infection
    K-252b, an indolocarbazole isolated from the actinomycete Nocardiopsis, is a PKC inhibitor. K-252b can be used to inhibit extracellular kinases of cells in culture because it can’t pass through cell membrane freely .
    K-252b
  • HY-130748
    K-252d

    		PKC Phosphodiesterase (PDE) Infection
    K-252d is an indolocarbazole alkaloid found in Nocardiopsis. It is a PKC inhibitor that inhibits PKC isolated from rat brain (IC50=350 nM). It also inhibits calcium- and calmodulin-dependent phosphodiesterase isolated from bovine heart (IC50=46.2 μM).
    K-252d

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: